Cited by 544Diabetes Treatment and ManagementBone health and osteoporosis researchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Open access

Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong, Heise, Mark A., Aftring, R. Paul, Viberti, Giancarlo, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group·2008·Diabetes Care

DOI 10.2337/dc07-2270

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE—The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). RESEARCH DESIGN AND METHODS—Data from the 1,840 women and 2,511 men randomly assigned in ADOPT to rosiglitazone, metformin, or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence, and sites of fractures. RESULTS—In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74 per 100 patient-years), metformin in 30 patients (5.1%, 1.54 per 100 patient-years), and glyburide in 21 patients (3.5%, 1.29 per 100 patient-years). The cumulative incidence (95% CI) of fractures in women at 5 years was 15.1% (11.2–19.1) with rosiglitazone, 7.3% (4.4–10.1) with metformin, and 7.7% (3.7–11.7) with glyburide, representing hazard ratios (95% CI) of 1.81 (1.17–2.80) and 2.13 (1.30–3.51) for rosiglitazone compared with metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and fractures were seen predominantly in the lower and upper limbs. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified. CONCLUSIONS—Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc07-2270

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Self-citation
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., Yamaguchi, M., Chung, U., Kubota, N., Terauchi, Y., Harada, Y., Azuma, Y., Nakamura, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19900 · Cited by 869
Older Women with Diabetes Have an Increased Risk of Fracture: A Prospective Study
Schwartz, A. V., Sellmeyer, D. E., Ensrud, K. E., Cauley, J. A., Tabor, H. K., Schreiner, P. J., Jamal, S. A., Black, D. M., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.1.7139 · Cited by 788
PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
Akune, T., Ohba, S., Kamekura, S., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200419900 · Cited by 730
Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study.
Bonds, D., Larson, J. C., Schwartz, A., Strotmeyer, E., Robbins, J. A., Rodríguez, B., Johnson, K. C., & Margolis, K. (2006) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2006-0614 · Cited by 602
Type 1 and Type 2 Diabetes and Incident Hip Fractures in Postmenopausal Women
Nicodemus, K. K., & Folsom, A. R. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1192 · Cited by 569
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka‐Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L. D., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 499
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Lecka‐Czernik, B., Gubrij, I. B., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., & Jilka, R. L. (1999) · PubMed · Cited by 464
Bone Is a Target for the Antidiabetic Compound Rosiglitazone
Rzońca, S., Suva, L. J., Gaddy, D., Montague, D. C., & Lecka‐Czernik, B. (2003) · Endocrinology · doi:10.1210/en.2003-0746 · Cited by 455
Rosiglitazone Causes Bone Loss in Mice by Suppressing Osteoblast Differentiation and Bone Formation
Ali, A., Weinstein, R. S., Stewart, S. A., PARFITT, A. M., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2004-0735 · Cited by 444

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

Snedecor GW, Cochran WG: Statistical Methods. 7th ed. Ames, Iowa, Iowa State University Press, 1980

Sorted by citations

Items 201–300 of 544

Orexin Regulates Bone Remodeling via a Dominant Positive Central Action and a Subordinate Negative Peripheral Action
Wei, W., Motoike, T., Krzeszinski, J. Y., Jin, Z., Xie, X., Dechow, P. C., Yanagisawa, M., & Wan, Y. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.03.016 · Cited by 41
Oral Antihyperglycemic Treatment Options for Type 2 Diabetes Mellitus
Brietzke, S. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.012 · Cited by 44
Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment
Dutta, M., Pakhetra, R., & Garg, M. (2012) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(11)60120-2 · Cited by 42
Trends in Antihyperglycemic Medication Prescriptions and Hypoglycemia in Older Adults: 2002-2013
Clemens, K. K., Shariff, S. Z., Liu, K., HRAMIAK, I. M., Mahon, J. L., McArthur, E., & Garg, A. X. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137596 · Cited by 42
Rosiglitazone Inhibits Bone Regeneration and Causes Significant Accumulation of Fat at Sites of New Bone Formation
Liu, L., Aronson, J., Huang, S., Lu, Y., Czernik, P. J., Rahman, S., Kolli, V., Suva, L. J., & Lecka‐Czernik, B. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9623-4 · Cited by 42
Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism
Lee, H. S., & Hwang, J. S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01361-5 · Cited by 41
Balancing Risk and Benefit with Oral Hypoglycemic Drugs
Hamnvik, O. R., & McMahon, G. T. (2009) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20116 · Cited by 44
Special considerations for treatment of type 2 diabetes mellitus in the elderly
Fravel, M. A., McDanel, D. L., Ross, M. B., Moores, K. G., & Starry, M. J. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080085 · Cited by 42
Diabetes and bone health
Antonopoulou, M., Bahtiyar, G., Banerji, M. A., & Sacerdote, A. S. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.04.004 · Cited by 41
Epidemiology and correlates of osteoporotic fractures among type 2 diabetic patients
Goldshtein, I., Nguyen, A. M., DePapp, A., Ish‐Shalom, S., Chandler, J. M., Chodick, G., & Shalev, V. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0432-x · Cited by 41
Impact of conjugated linoleic acid on bone physiology: proposed mechanism involving inhibition of adipogenesis
Ing, S. W., & Belury, M. A. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00376.x · Cited by 40
Long‐term use of dipeptidyl peptidase‐4 inhibitors and risk of fracture: A retrospective population‐based cohort study
Driessen, J. H. M., van den Bergh, J. P., van Onzenoort, H. A. W., Henry, R. M. A., Leufkens, H. G. M., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12843 · Cited by 40
Bone and bone marrow: The same organ
Fattore, A. D., Capannolo, M., & Rucci, N. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.07.020 · Cited by 42
Long‐term glycaemic control with metformin–sulphonylurea–pioglitazone triple therapy in PROactive (PROactive 17)
Scheen, A. J., Tan, M. H., Betteridge, D. J., Birkeland, K. I., Schmitz, O., Charbonnel, B. H., & on behalf of the PROactive investigators (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02816.x · Cited by 39
Safety of Antidiabetic Therapies on Bone
Lecka‐Czernik, B. (2012) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-012-9129-7 · Cited by 38
The forgotten type 2 diabetes mellitus medicine: rosiglitazone
Xu, B., Xing, A., & Li, S. (2021) · Diabetology International · doi:10.1007/s13340-021-00519-0 · Cited by 38
Diabetes and oral therapies
Alhadramy, M. S. (2016) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2016.02.001 · Cited by 40
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial
Bray, G. A., Smith, S. R., Banerji, M. A., Tripathy, D., Clément, S., Buchanan, T. A., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., Musi, N., et al. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12099 · Cited by 38
The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies
Amatruda, M., Gembillo, G., Giuffrida, A. E., Santoro, D., & Conti, G. (2021) · Medicina · doi:10.3390/medicina57090868 · Cited by 38
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
Carta, A. R., & Simuni, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.963195 · Cited by 36
Fracture risk associated with common medications used in treating type 2 diabetes mellitus
Wolverton, D., & Blair, M. M. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160319 · Cited by 36
Robust Trabecular Microstructure in Type 2 Diabetes Revealed by Individual Trabecula Segmentation Analysis of HR-pQCT Images
Starr, J. F., Bandeira, L., Agarwal, S., Shah, A. M., Nishiyama, K. K., Hu, Y., McMahon, D. J., Guo, X.-D. E., Silverberg, S. J., & Rubin, M. R. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3465 · Cited by 38
Inverse association of PPARγ agonists use and high grade glioma development
Grommes, C., Conway, D. S., Alshekhlee, A., & Barnholtz‐Sloan, J. S. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0185-x · Cited by 36
Review article: effects of type 2 diabetes therapies on bone metabolism
Vianna, A. G. D., Sanches, C. P., & Barreto, F. C. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0274-5 · Cited by 36
Type 2 diabetes and bone fragility- An under-recognized association
Farooqui, K. J., Mithal, A., Kwee, A. K., & Chandran, M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.04.017 · Cited by 36
Structure and Function of Bone Marrow Adipocytes
de Paula, F. J. A., & Rosen, C. J. (2017) · Comprehensive physiology · doi:10.1002/cphy.c170010 · Cited by 39
Osteoporosis and polypharmacy
Gosch, M., Jeske, M. R., Kammerlander, C., & Roth, T. (2012) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-012-0374-7 · Cited by 34
Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study
Pritchard, J. M., Giangregorio, L., Atkinson, S. A., BEATTIE, K. A., Inglis, D., Ioannidis, G., Gerstein, H. C., Punthakee, Z., Adachi, J. D., & Παπαϊωάννου, Α. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-114 · Cited by 38
Pathophysiological role of enhanced bone marrow adipogenesis in diabetic complications
Piccinin, M. A., & Khan, Z. A. (2014) · Adipocyte · doi:10.4161/adip.32215 · Cited by 39
Bone marrow mesenchymal stem cells: Fat on and blast off by FGF21
Wan, Y. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.12.014 · Cited by 34
Impact of pioglitazone on bone mineral density and bone marrow fat content
Pop, L. M., Lingvay, I., Yuan, Q., Li, X., ADAMS-HUET, B. A., & Maalouf, N. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4164-3 · Cited by 37
Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54‐week study
Yoon, K., Steinberg, H. O., Teng, R., Golm, G. T., Lee, M. M.-S., O’Neill, E. A., Kaufman, K. D., & Goldstein, B. J. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01594.x · Cited by 33
Noninsulin Treatment of Type 2 Diabetes Mellitus in Geriatric Patients: A Review
Germino, F. W. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.10.020 · Cited by 34
Clinical Management of Elderly Patients with Type 2 Diabetes Mellitus
Pratley, R. E., & Gilbert, M. P. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.01.2526 · Cited by 35
COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
Gao, L., Zhao, F.-L., & Li, S. (2012) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462312000608 · Cited by 33
Bone Loss and Fracture Risk Associated with Thiazolidinedione Therapy
Riche, D. M., & King, S. T. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.7.716 · Cited by 33
The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice
Wang, C., Hong, L., Chen, S., He, J., Sheng, C., Cheng, X., Qu, S., Wang, K., Lü, M., & Yu, Y. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0374-0 · Cited by 32
A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice
Wu, D., Eeda, V., Undi, R. B., Mann, S. N., Stout, M., Lim, H., & Wang, W. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101363 · Cited by 34
Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
Vinke, J. S. J., Heerspink, H. J. L., & de Borst, M. H. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000505 · Cited by 32
Long‐term glycaemic effects of pioglitazone compared with placebo as add‐on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)
Scheen, A. J., Tan, M. H., Betteridge, D. J., Birkeland, K. I., Schmitz, O., Charbonnel, B. H., & on behalf of the PROactive investigators (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02857.x · Cited by 32
Influence of diabetes on tissue healing in orthopaedic injuries
Stolarczyk, A., Sarzyńska, S., Gondek, A., & Cudnoch‐Jędrzejewska, A. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12939 · Cited by 31
Wolfram Syndrome: A Case Report and Review of Clinical Manifestations, Genetics Pathophysiology, and Potential Therapies
Toppings, N. B., McMillan, J. M., Au, P. Y. B., Suchowersky, O., & Donovan, L. (2018) · Case Reports in Endocrinology · doi:10.1155/2018/9412676 · Cited by 31
Glycaemic goals in patients with type 2 diabetes: current status, challenges and recent advances
Khunti, K., & Davies, M. J. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01186.x · Cited by 31
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
Schernthaner, G.-H. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02025.x · Cited by 30
Bone: Incretin Hormones Perceiver or Receiver?
Dicembrini, I., Mannucci, E., & Rotella, C. M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/519784 · Cited by 30
Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats
Eom, Y. S., Gwon, A., Kwak, K. M., Kim, J., Yu, S. H., Lee, S., Kim, Y. S., Park, I. B., Kim, K., Lee, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168569 · Cited by 30
Safety of PPAR Agonists
Home, P. (2011) · Diabetes Care · doi:10.2337/dc11-s233 · Cited by 29
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.
Brunetti, L., & Kalabalik, J. (2012) · PubMed Central · Cited by 30
On the Metabolically Active Form of Metaglidasen: Improved Synthesis and Investigation of Its Peculiar Activity on Peroxisome Proliferator‐Activated Receptors and Skeletal Muscles
Laghezza, A., Montanari, R., Lavecchia, A., Piemontese, L., Pochetti, G., Iacobazzi, V., Infantino, V., Capelli, D., Bellis, M. D., Liantonio, A., et al. (2015) · ChemMedChem · doi:10.1002/cmdc.201402462 · Cited by 28
Increased Risk of Nonunion and Charcot Arthropathy After Ankle Fracture in People With Diabetes
Lavery, L. A., Lavery, D. C., Green, T., Hunt, N. A., Fontaine, J. L., Kim, P. J., & Wukich, D. K. (2020) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2019.05.006 · Cited by 28
Anti-diabetic effects including diabetic nephropathy of anti-osteoporotic trace minerals on diabetic mice
Maehira, F., Ishimine, N., Miyagi, I., Eguchi, Y., Shimada, K., Kawaguchi, D., & Oshiro, Y. (2010) · Nutrition · doi:10.1016/j.nut.2010.04.007 · Cited by 29
PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis
Alnuaimi, S., Reljic, T., Abdulla, F. S., Memon, H., Al-Ali, S., Smith, T., Serdarević, F., Velija-Ašimi, Z., Kumar, A., & Semiz, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-59390-z · Cited by 30
Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function
Alba, M., Åhrén, B., Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O’Neill, E. A., Williams‐Herman, D., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12145 · Cited by 27
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Update on Safety Issues Related to Antihyperglycemic Therapy
Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 27
Drugs for type 2 diabetes: role in the regulation of bone metabolism
Mannucci, E. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.130 · Cited by 23
Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro
Yi, W., Shi, J., Zhao, G., Zhou, X. E., Suino-Powell, K. M., Melcher, K., & Xu, H. E. (2017) · Scientific Reports · doi:10.1038/srep41487 · Cited by 26
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
Lópes, R. D., Dickerson, S., Hafley, G. E., Burns, S., Tourt-Uhlig, S., White, J., Newby, L. K., Michel Komajda, N., McMurray, J. J. V., Bigelow, R., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.005 · Cited by 25
Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials
Stojanović, M., Prostran, M. S., & Radenković, M. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1999-4 · Cited by 25
Peroxisome proliferator-activated receptor γ enhances adiponectin secretion via up-regulating DsbA-L expression
Jin, D., Sun, J., Huang, J., Yu, X., An, Y., He, Y., Li, Q., & Yang, Z. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.04.015 · Cited by 24
Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2)
Stechschulte, L. A., Ge, C., Hinds, T. D., Sánchez, E. R., Franceschi, R. T., & Lecka‐Czernik, B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752493 · Cited by 24
Retracted
The Effect of Type 2 Diabetes on Bone Biomechanics
Karim, L., Rezaee, T., & Vaidya, R. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00526-w · Cited by 24
Orthopedic complications in diabetes
Gehling, D. J., Lecka‐Czernik, B., & Ebraheim, N. A. (2015) · Bone · doi:10.1016/j.bone.2015.07.029 · Cited by 24
The effects of diabetes therapy on bone: A clinical perspective
Kheniser, K. G., Santos, C. M. P., & Kashyap, S. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.04.005 · Cited by 24
Time‐dependent risk of fracture in adults with type 2 diabetes receiving anti‐diabetic drug: A one‐stage network meta‐analysis
Shen, Y., Shi, Q., Zou, X., Meng, W., Tian, H., Du, L., & Li, S. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3780 · Cited by 23
Prevention and treatment of nonalcoholic fatty liver disease
Targher, G., Bellis, A., Fornengo, P., Ciaravella, M. F., Pichiri, I., Perin, P. C., Trimarco, B., & Marchesini, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.02.004 · Cited by 23
Clinical Risk Factors for Fracture in Diabetes: A Matched Cohort Analysis
Fraser, L.-A., Pritchard, J. M., Ioannidis, G., Giangegorio, L. M., Adachi, J. D., Παπαϊωάννου, Α., & Leslie, W. D. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2011.06.007 · Cited by 23
Marrow Fat—a New Target to Treat Bone Diseases?
Lecka-Czernik, B., Baroi, S., Stechschulte, L. A., & Chougule, A. S. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0426-z · Cited by 23
Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes
Vilar, L., Canadas, V., Arruda, M. J., Arahata, C. M., Agra, R., Pontes, L., Montenegro, L., Vilar, C. F., Silva, L. M. E., Albuquerque, J. L., et al. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000300010 · Cited by 24
The Effect of Rosiglitazone on Bone Mass and Fragility Is Reversible and Can Be Attenuated With Alendronate
Kumar, S., Hoffman, S. J., Samadfam, R., Mansell, P., Jolette, J., Smith, S. Y., Guldberg, R. E., & Fitzpatrick, L. A. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1918 · Cited by 22
RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes
Iwamoto, J., Satō, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.03.033 · Cited by 22
Retracted
Metformin: Is It the Well Wisher of Bone Beyond Glycemic Control in Diabetes Mellitus?
Shaik, A. R., Singh, P., Shaik, C., Kohli, S., Vohora, D., & Ferrari, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00805-8 · Cited by 22
Discovery of a Peroxisome Proliferator Activated Receptor γ (PPARγ) Modulator with Balanced PPARα Activity for the Treatment of Type 2 Diabetes and Dyslipidemia
Liu, W., Liu, K., Wood, H. B., McCann, M. E., Doebber, T. W., Chang, C. H., Akiyama, T. E., Einstein, M., Berger, J. P., & Meinke, P. T. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900367w · Cited by 22
Management of Blood Glucose with Noninsulin Therapies in Type 2 Diabetes.
George, C. M., Brujin, L. L., Will, K. J., & Howard-Thompson, A. (2015) · PubMed · Cited by 22
Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT)
Napoli, N., Incalzi, R. A., Gennaro, G., Marcocci, C., Marfella, R., Papalia, R., Purrello, F., Ruggiero, C., Tarantino, U., Tramontana, F., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.01.019 · Cited by 22
Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies
Cugno, C., Kizhakayil, D., Calzone, R., Rahman, S. M., Halade, G. V., & Rahman, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89827-8 · Cited by 23
Exploring Rosiglitazone’s Potential to Treat Alzheimer’s Disease through the Modulation of Brain-Derived Neurotrophic Factor
Nelson, M. L., Pfeifer, J. A., Hickey, J. P., Collins, A. E., & Kalisch, B. E. (2023) · Biology · doi:10.3390/biology12071042 · Cited by 22
Thiazolidinediones in prediabetes and early type 2 diabetes: What can be learned about that disease’s pathogenesis
Leahy, J. L. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0035-4 · Cited by 20
Pharmacology and in Vitro Profiling of a Novel Peroxisome Proliferator-Activated Receptor .GAMMA. Ligand, Cerco-A
Wakabayashi, K., Hayashi, S., Matsui, Y., Matsumoto, T., Furukawa, A., Kuroha, M., Tanaka, N., Inaba, T., Kanda, S., Tanaka, J., et al. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1094 · Cited by 21
Osteoporosis Update: Proceedings of the 2013 Santa Fe Bone Symposium
Lewiecki, E. M., Bilezikian, J. P., Bonewald, L. F., Compston, J. E., Heaney, R. P., Kiel, D. P., Miller, P. D., & Schousboe, J. T. (2014) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.11.006 · Cited by 21
Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
Montanari, R., Capelli, D., Tava, A., Galli, A., Laghezza, A., Tortorella, P., Loiodice, F., & Pochetti, G. (2016) · Scientific Reports · doi:10.1038/srep27658 · Cited by 21
Current Therapies for the Medical Management of Diabetes
Inzucchi, S. E., & Majumdar, S. K. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001332 · Cited by 21
Exercise initiated after the onset of insulin resistance improves trabecular microarchitecture and cortical bone biomechanics of the tibia in hyperphagic Otsuka Long Evans Tokushima Fatty rats
Ortinau, L. C., Linden, M. A., Dirkes, R. K., Rector, R. S., & Hinton, P. S. (2017) · Bone · doi:10.1016/j.bone.2017.07.010 · Cited by 20
Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration
Liu, L., Aronson, J., & Lecka‐Czernik, B. (2012) · Bone · doi:10.1016/j.bone.2012.09.038 · Cited by 20
Effect of type 2 diabetes medications on fracture risk
Guja, C., Guja, L., & Miulescu, R. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.51 · Cited by 20
Advanced glycation endproducts and bone quality: practical implications for people with type 2 diabetes
Moseley, K. F., Du, Z., Sacher, S. E., Ferguson, V. L., & Donnelly, E. L. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000641 · Cited by 20
Should biochemical markers of bone turnover be considered standard practice for safety pharmacology?
Henriksen, K., Bohren, K. M., Bay‐Jensen, A., & Karsdal, M. A. (2009) · Biomarkers · doi:10.3109/13547500903434519 · Cited by 20
The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case–control study
Hsiao, F., & Mullins, C. D. (2009) · Diabetologia · doi:10.1007/s00125-009-1609-z · Cited by 20
Nutrition and metabolism
Bhatnagar, D., & Bhatnagar, P. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328355ee48 · Cited by 21
Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales
Reyes‐García, R., Gimeno, E. J., Martín, A. G., Muñoz, M. R., Sáez, J. M. G., Fernández, I. L., Varsavsky, M., Iglesias, S. G., Rodríguez, I. C., Ballesteros-Pomar, M. D., et al. (2012) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.01.002 · Cited by 19
Marine Natural and Nature-Inspired Compounds Targeting Peroxisome Proliferator Activated Receptors (PPARs)
D’Aniello, E., Amodeo, P., & Vitale, R. M. (2023) · Marine Drugs · doi:10.3390/md21020089 · Cited by 19
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States
Lee, W. C., Conner, C., & Hammer, M. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.08.010 · Cited by 18
Effects of Rosiglitazone vs Metformin on Circulating Osteoclast and Osteogenic Precursor Cells in Postmenopausal Women with Type 2 Diabetes Mellitus
Rubin, M. R., Manavalan, J. S., Agarwal, S., McMahon, D. J., Nino, A., Fitzpatrick, L. A., & Bilezikian, J. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3666 · Cited by 20
Long-term effects of lifestyle and metformin interventions in DPP on bone density
Schwartz, A. V., Pan, Q., Aroda, V. R., Crandall, J. P., Kriska, A. M., Piromalli, C. S., Wallia, A., Temprosa, M. G., & Florez, H. J. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05989-1 · Cited by 19
Drugs Interfering with Insulin Resistance and Their Influence on the Associated Hypermetabolic State in Severe Burns: A Narrative Review
Greabu, M., Bădoiu, S. C., Stănescu-Spînu, I.-I., Miricescu, D., Totan, A., Badoiu, S. E., Costagliola, M., & Jinga, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189782 · Cited by 21
The benefits of adipocyte metabolism in bone health and regeneration
Burkhardt, L.-M., Bucher, C. H., Löffler, J., Rinne, C., Duda, G. N., Geißler, S., Schulz, T. J., & Schmidt‐Bleek, K. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1104709 · Cited by 21
The use of metformin, sulfonylurea compounds and insulin and the risk of hip fractures in diabetic patients: a systematic review and meta-analysis of observational studies
Bahardoust, M., Yarali, M., Donyadideh, G., Rahimi, E., Naderi, D., Tehrani, F. M., & Delpisheh, A. (2023) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-023-06493-9 · Cited by 18
Frailty and Safety
Abbatecola, A. M., Olivieri, F., Corsonello, A., Strollo, F., Fumagalli, A., & Lattanzio, F. (2012) · Drug Safety · doi:10.1007/bf03319104 · Cited by 19
Add-on therapies to metformin for type 2 diabetes
Shomali, M. E. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.542150 · Cited by 18
Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes
Wilson, J. E., Kurukulasuriya, R., Sinz, C. J., Lombardo, M., Bender, K., Parker, D. L., Sherer, E. C., Costa, M., Dingley, K. H., Li, X., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.018 · Cited by 18

Authors: Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., Viberti, G., & for the A Diabetes Outcome Progression Trial (ADOPT) Study Group
Affiliations: University of Washington (US)
Mount Sinai Hospital (CA)
George Washington University (US)
The University of Texas at San Antonio Health Science Center (US)
University of Michigan (US)
Oxford Centre for Diabetes, Endocrinology and Metabolism (GB)
GlaxoSmithKline (United States) (US)
King's College London (GB)
ORCID: Kahn, Steven E.
Zinman, Bernard
Lachin, John M.
Herman, William H.
Holman, Rury R.
Yu, Dahong
Heise, Mark A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2008-05-01
Volume: 31
Issue: 5
Pages: 845-851
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc07-2270
OpenAlex: W2099673402
Cited by: 537
References: 22
Citations by year: 2026: 7 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 17 · 2021: 30 · 2020: 18 · 2019: 19 · 2018: 36 · 2017: 31 · 2016: 31 · 2015: 31 · 2014: 40 · 2013: 43 · 2012: 41
FWCI: 39.37
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: rosiglitazone, fracture, type 2 diabetes, ADOPT trial, metformin, glibenclamide, sex differences, women, fracture risk factors, bone fragility, thiazolidinediones
MeSH terms: Rosiglitazone, Aged, Diabetes Mellitus, Type 2, Female, Glyburide, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Treatment Outcome, Age of Onset, Disease Progression, Thiazolidinediones, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rosiglitazone-Associated Fractures in Type 2 Diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks